Elizabeth Colston
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Psoriasis: Treatment and Pathogenesis, Cytokine Signaling Pathways and Interactions, Autoimmune Bullous Skin Diseases, Synthesis and biological activity, Hepatitis C virus research
Most-Cited Works
- → Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)*(2019)232 cited
- → Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab(2019)184 cited
- → Soluble receptor-resistant poliovirus mutants identify surface and internal capsid residues that control interaction with the cell receptor.(1994)100 cited
- → Poliovirus variants selected on mutant receptor-expressing cells identify capsid residues that expand receptor recognition(1995)74 cited
- → Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2)(2024)40 cited
- → Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies(2017)31 cited
- → The Effect of Hepatic Impairment on the Pharmacokinetics of Asunaprevir, an HCV NS3 Protease Inhibitor(2014)30 cited
- → Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open‐label, phase 3 trial(2024)30 cited
- → Integration of the BALB/c ecotropic provirus into the colony-stimulating factor-1 growth factor locus in a myc retrovirus-induced murine monocyte tumor(1988)27 cited
- → POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY(2021)26 cited